Literature DB >> 30343433

Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.

Anna M Pietroboni1,2,3, Tiziana Carandini4,5,6, Annalisa Colombi4,5,6, Matteo Mercurio4, Laura Ghezzi4,5,6, Giovanni Giulietti7, Marta Scarioni4,5,6, Andrea Arighi4,5,6, Chiara Fenoglio5, Milena A De Riz4,5,6, Giorgio G Fumagalli4,5,6,8, Paola Basilico4,5,6, Maria Serpente5, Marco Bozzali7,9, Elio Scarpini4,5,6, Daniela Galimberti4,5,6, Giorgio Marotta4,5.   

Abstract

PURPOSE: The disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid1-42 (Aβ) levels, amyloid tracer uptake, and brain volumes.
METHODS: Twelve MS patients were recruited and divided according to their disease activity into active and non-active groups. All participants underwent neurological examination, neuropsychological testing, lumbar puncture, brain magnetic resonance (MRI) imaging, and 18F-florbetapir PET. Aβ levels were determined in CSF samples from all patients. MRI and PET images were co-registered, and mean standardized uptake values (SUV) were calculated for each patient in the NAWM and in the DWM. To calculate brain volumes, brain segmentation was performed using statistical parametric mapping software. Nonparametric statistical analyses for between-group comparisons and regression analyses were conducted.
RESULTS: We found a lower SUV in DWM compared to NAWM (p < 0.001) in all patients. Decreased NAWM-SUV was observed in the active compared to non-active group (p < 0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV (p = 0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV (r = 0.79; p = 0.01) and NAWM volume (r = 0.81, p = 0.01).
CONCLUSIONS: The correlation between CSF Aβ levels and NAWM-SUV suggests that the predictive role of β-amyloid may be linked to early myelin damage and may reflect disease activity and clinical progression.

Entities:  

Keywords:  Amyloid; Amyloid tracer; Florbetapir; Multiple sclerosis; PET; White matter

Mesh:

Substances:

Year:  2018        PMID: 30343433     DOI: 10.1007/s00259-018-4182-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis.

Authors:  Paul Schmidt; Christian Gaser; Milan Arsic; Dorothea Buck; Annette Förschler; Achim Berthele; Muna Hoshi; Rüdiger Ilg; Volker J Schmid; Claus Zimmer; Bernhard Hemmer; Mark Mühlau
Journal:  Neuroimage       Date:  2011-11-18       Impact factor: 6.556

2.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Authors:  Adam S Fleisher; Kewei Chen; Xiaofen Liu; Auttawut Roontiva; Pradeep Thiyyagura; Napatkamon Ayutyanont; Abhinay D Joshi; Christopher M Clark; Mark A Mintun; Michael J Pontecorvo; P Murali Doraiswamy; Keith A Johnson; Daniel M Skovronsky; Eric M Reiman
Journal:  Arch Neurol       Date:  2011-07-11

3.  BREMSO: a simple score to predict early the natural course of multiple sclerosis.

Authors:  R Bergamaschi; C Montomoli; G Mallucci; A Lugaresi; G Izquierdo; F Grand'Maison; P Duquette; V Shaygannejad; R Alroughani; P Grammond; C Boz; G Iuliano; C Zwanikken; T Petersen; J Lechner-Scott; R Hupperts; H Butzkueven; E Pucci; C Oreja-Guevara; E Cristiano; M P Pia Amato; E Havrdova; R Fernandez-Bolanos; T Spelman; M Trojano
Journal:  Eur J Neurol       Date:  2015-03-25       Impact factor: 6.089

4.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

5.  The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population.

Authors:  B Goretti; F Patti; S Cilia; F Mattioli; C Stampatori; C Scarpazza; M P Amato; E Portaccio
Journal:  Neurol Sci       Date:  2013-10-08       Impact factor: 3.307

Review 6.  Multiple sclerosis: lessons from molecular neuropathology.

Authors:  Hans Lassmann
Journal:  Exp Neurol       Date:  2013-12-14       Impact factor: 5.330

7.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 8.  Remyelination in the CNS: from biology to therapy.

Authors:  Robin J M Franklin; Charles Ffrench-Constant
Journal:  Nat Rev Neurosci       Date:  2008-11       Impact factor: 34.870

9.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

Review 10.  Amyloid Proteins and Their Role in Multiple Sclerosis. Considerations in the Use of Amyloid-PET Imaging.

Authors:  Jordi A Matías-Guiu; Celia Oreja-Guevara; María Nieves Cabrera-Martín; Teresa Moreno-Ramos; José Luis Carreras; Jorge Matías-Guiu
Journal:  Front Neurol       Date:  2016-03-31       Impact factor: 4.003

View more
  15 in total

1.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

2.  A new frontier for amyloid PET imaging: multiple sclerosis.

Authors:  Silvia Morbelli; Matteo Bauckneht; Selene Capitanio; Matteo Pardini; Luca Roccatagliata; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-15       Impact factor: 9.236

3.  Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.

Authors:  Sylvain Auvity; Matteo Tonietto; Fabien Caillé; Benedetta Bodini; Michel Bottlaender; Nicolas Tournier; Bertrand Kuhnast; Bruno Stankoff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-04       Impact factor: 9.236

4.  Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.

Authors:  Alexis Moscoso; Michel J Grothe; Michael Schöll
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-21       Impact factor: 9.236

Review 5.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

6.  Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.

Authors:  Elisa Schmidt; Christian Schinke; Michael Rullmann; Julia Luthardt; Georg-Alexander Becker; Sarah Haars; Muriel Stoppe; Donald Lobsien; Karl-Titus Hoffmann; Osama Sabri; Swen Hesse; Florian Then Bergh
Journal:  Sci Rep       Date:  2020-09-04       Impact factor: 4.379

7.  Evaluation of Myelin Radiotracers in the Lysolecithin Rat Model of Focal Demyelination: Beware of Pitfalls!

Authors:  Min Zhang; Gaëlle Hugon; Caroline Bouillot; Radu Bolbos; Jean-Baptiste Langlois; Thierry Billard; Frédéric Bonnefoi; Biao Li; Luc Zimmer; Fabien Chauveau
Journal:  Contrast Media Mol Imaging       Date:  2019-05-29       Impact factor: 3.161

8.  18F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis.

Authors:  Min Zhang; Jun Liu; Biao Li; Sheng Chen
Journal:  EJNMMI Res       Date:  2019-11-12       Impact factor: 3.138

Review 9.  Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.

Authors:  Matteo Bauckneht; Selene Capitanio; Stefano Raffa; Luca Roccatagliata; Matteo Pardini; Caterina Lapucci; Cecilia Marini; Gianmario Sambuceti; Matilde Inglese; Paolo Gallo; Diego Cecchin; Flavio Nobili; Silvia Morbelli
Journal:  EJNMMI Radiopharm Chem       Date:  2019-04-08

Review 10.  Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis.

Authors:  Maria Petracca; Giuseppe Pontillo; Marcello Moccia; Antonio Carotenuto; Sirio Cocozza; Roberta Lanzillo; Arturo Brunetti; Vincenzo Brescia Morra
Journal:  Brain Sci       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.